Nesidiocoris tenuis in Burkina Faso: Distribution, predatory capacity and insecticide sensibility

Tuta absoluta (Lepidoptera: Gelechiidae) is a worldwide invasive insect species, considered a major pest of tomato. It has recently established in Burkina Faso, where chemical control remains the only affordable option to limit damage. Nesidiocoris tenuis (Hemiptera: Miridae) is commercialised as a biological agent to control this pest in other parts of the world. But no literature is available on this predator in Burkina Faso. Therefore, in this study, we (1) scoured the country to determine its distribution and abundance in tomato fields, (2) verified its ability to consume T. absoluta eggs in two scenarios: the first one where N. tenuis has to search for the eggs on the plants and the second one in Petri dishes where the eggs are placed and N. tenuis could consume the eggs at will (3) measure the susceptibility of both insects to insecticides (two synthetic insecticides, three bio-bacterial insecticides and eight plant extracts) using the IRAC 022 method. It appears that, N. tenuis was found in 13 regions of the country with very interesting densities in some tomato fields (up to 80 individuals / m2). All stages of N. tenuis consume T. absoluta eggs and the number of eggs consumed depends on the stage of development and mode of egg delivery. When he has to look for some on the leaves, the adults find about 20 eggs to consume per day, while for an availability and consumption at will of eggs, he consumes about 45 eggs per day. Abamectin, emamectin benzoate, spinosad, spinetoram were very toxic for both T. absoluta and N. tenuis. In contrast, biopesticides including Bacillus thuringiensis, neem oil, Cleome viscosa, Ocimum basilicum and Cassia occidentalis were found to be compatible with N. tenuis while controlling T. absoluta. Based on our results, we recommend that through training for growers, they can be shown the importance of N. tenuis in the management of T. absoluta. We therefore recommend the use of biopesticides in combination with N. tenuis in the control of T. absoluta in Burkina Faso.Production Durable Intégrant la Recherche (ProDuIRe

Non-Perturbative Mass Renormalization in Quenched QED from the Worldline Variational Approach

Following Feynman's successful treatment of the polaron problem we apply the same variational principle to quenched QED in the worldline formulation. New features arise from the description of fermions by Grassmann trajectories, the supersymmetry between bosonic and fermionic variables and the much more singular structure of a renormalizable gauge theory like QED in 3+1 dimensions. We take as trial action a general retarded quadratic action both for the bosonic and fermionic degrees of freedom and derive the variational equations for the corresponding retardation functions. We find a simple analytic, non-perturbative, solution for the anomalous mass dimension gamma_m(alpha) in the MS scheme. For small couplings we compare our result with recent four-loop perturbative calculations while at large couplings we find that gamma_m(alpha) becomes proportional to (alpha)^(1/2). The anomalous mass dimension shows no obvious sign of the chiral symmetry breaking observed in calculations based on the use of Dyson-Schwinger equations, however we find that a perturbative expansion of gamma_m(alpha) diverges for alpha > 0.7934. Finally, we investigate the behaviour of gamma_m(alpha) at large orders in perturbation theory.Comment: 18 pages, 1 Figure, RevTeX; the manuscript has been substantially revised and enlarged in order to make it selfcontained; accepted for publication in Phys. Rev.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Nesidiocoris tenuis in Burkina Faso: Distribution, predatory capacity and insecticide sensibility

Tuta absoluta (Lepidoptera: Gelechiidae) is a worldwide invasive insect species, considered a major pest of tomato. It has recently established in Burkina Faso, where chemical control remains the only affordable option to limit damages. Nesidiocoris tenuis (Hemiptera: Miridae) is commercialized as a biological agent to control this pest in other parts of the world. But very limited information exists on this predator in Burkina Faso. In this study, we first performed an insect survey in all agricultural regions areas of the country, and we found N. tenuis to be widely observed in all of them. Then, we performed two laboratory bioassays and demonstrated that all instars preyed on T. absoluta eggs, whether they were fed ad libitum or they had to actively forage for their prey. Because insecticide tolerant populations of T. absoluta were recently identified, we finally aimed at identifying agrochemicals that do not harm N. tenuis. We evaluated the toxicity of two synthetic insecticides, three bio-bacterial insecticides and eight plant extracts, all being active ingredients available on the local market. Most of them (i.e., abamectin, emamectin benzoate, spinosad, spinetoram) were highly toxic for both T. absoluta and N. tenuis. In contrast, Bacillus thuringiensis var. Kurstaki, neem oil, Cleome viscosa (Asian spiderflower), Ocimum basilicum (Basil) and Cassia occidentalis (Coffee senna) were compatible with N. tenuis while still controlling T. absoluta. Based on our results, we recommend the application of Bacillus thuringiensis to both control T. absoluta and which does not compromise the maintenance of N. tenuis populations

Digitization and image-based structure-properties relationship evaluation of a porous gold micro-electrode

The advantage of using porous materials for biofuel cells and biosensors is their very large internal surface area (where electron exchange takes place) compared to the overall material volume, yielding much larger current densities than on a bare solid electrode of the same size. However, limitations occur because of mass transfer resistance through the pores. We describe here a bottom-up approach to optimize the design of such materials, through the analysis and modeling of their porous structure. Electrodes prepared by replicating stacked Langmuir-Blodgett films, with 1-µm diameter interconnected spherical pores, were studied. Since pore window dimensions are around 100 nm, Focused Ion Beam-Scanning Electron Microscopy (FIB-SEM) has been performed to obtain a 3D reconstruction of the porous medium. Then, a determination of the geometrical characteristics has been achieved through image analysis. The structure of the sphere packing, the shape and size of the connections between spheres, the distances between spheres, the sphere diameters and the specific surface area have been analyzed. The porous medium is close to a face-centered cubic arrangement of spherical pores, but several deviations from ideality are present: missing pores (point defects), stacking errors (dislocations), and incomplete connection between spheres (only 50% of the ideal sphere connections are present). The consequence of such defects on transport are studied through image-based simulations of mass diffusion in the actual porous medium and in similar ideal media.Modélisation d'électrodes poreuses pour leur conception optimisé